![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Jupiter Wellness Inc | NASDAQ:JUPW | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.52 | 1.49 | 1.51 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C., 20549
FORM
(
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
(The Nasdaq Capital Market) | ||||
(The Nasdaq Capital Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Explanatory Note
This Amendment No. 1 on Form 8-K (“Amendment No. 1”) amends Exhibit 99.3 of the Form 8-K filed by Safety Shot, Inc. (the “Company”) on January 16, 2024 (the “January 16 Form 8-K”) in which the Company served its summons and complaint upon Capybara Research and Igor Appelboom via the filing of the January 16 Form 8-K and the publication of a press release, attached to the January 16 Form 8-K as Exhibit 99.1, pursuant to an Order in the matter of Safety Shot, Inc. v. Capybara Research et. al., Case No. 1:23-cv-10728-JSR (the “Capybara Action”).
This Amendment No. 1 hereby amends Exhibit 99.3 of the January 16 Form 8-K to rectify an error in the upload of the original Exhibit 99.3 to the January 16 Form 8-K.
The text and Exhibits 99.1, 99.2 and 99.4 of the January 16 Form 8-K are hereby incorporated by reference and contained hereinafter.
Item 7.01 Regulation FD Disclosure
On January 16, 2024, the Company issued a press release. A copy of the press release is furnished hereto as Exhibit 99.1 and incorporated herein by reference.
Item 8.01 Other Events
On January 10, 2024, The Honorable Jed S. Rakoff in the United States District Court for the Southern District of New York, entered an Order in the matter of Safety Shot, Inc. v. Capybara Research et. al., Case No. 1:23-cv-10728-JSR (the “Capybara Action”), ECF 24 (the Order”), permitting the Company to serve its summons and complaint upon Defendants Capybara Research and Igor Appelboom by filing this Form 8-K and publishing the press release, attached hereto as Exhibit 99.1. Pursuant to the Order, the filing of this Form 8-K, the summons attached hereto as Exhibit 99.2, the complaint attached hereto as Exhibit 99.3 and the Order attached hereto as Exhibit 99.4 shall provide the Constitutional requirement of actual notice of the Action to Defendants Capybara Research and Igor Appelboom pursuant to Rule 4(f)(3) of the Federal Rules of Civil Procedure.
Exhibits 9.01 Financial Statements and Exhibits
Exhibit No. | Description | |
99.1 | Press Release dated January 16, 2024 | |
99.2 | Summons | |
99.3 | Complaint | |
99.4 | Order | |
104 | Cover Page Interactive Data File (embedded with the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 6, 2024
SAFETY SHOT, INC. | ||
By: | /s/ Brian John | |
Brian John | ||
Chief Executive Officer |
Exhibit 99.1
Litigation Update - Safety Shot Authorized to Serve Notice of Action Against Capybara Research and Igor Appelboom by Public Disclosure and Press Release Pursuant to Court Order
JUPITER, FL - JANUARY 16, 2024 - On December 5, 2023, Safety Shot, Inc. (Nasdaq: SHOT) (“SHOT” or the “Company”) announced that it filed a federal lawsuit in the United States District Court for the Southern District of New York, Safety Shot, Inc. v. Capybara Research et. al., Case No. 1:23-cv-10728-JSR (the “Action”), against Capybara Research (“Capybara”), A firm that Safety Shot alleges was created for solely to lend “credibility” to its malicious and defamatory articles purposefully designed to negatively impact the share prices of publicly traded companies in which it holds short positions, and its previously anonymous owner and operator responsible for publishing the malicious and defamatory article authored and published on November 22, 2023 which attacked the Company and its directors leading to a 37.03% decline in the Company’s share price over the course of that day.
After commencing the Action, the Company’s counsel at The Basile Law Firm, P.C. discovered the true identity of the individual responsible for the article published on Capybara’s website and X (f/k/a Twitter) account to be an individual living in Brazil named Igor Appelboom (“Appelboom”). Appelboom previously operated an X account under his own name to which he posted content relating to the short selling of various securities.
Capybara and Appelboom take short positions in publicly trading companies and release fraudulent, disparaging reports in order to drive the company’s stock price down for their own financial benefit. Due to the short position Capybara disclosed in the article, Capybara and the previously anonymous owner and operator, Appelboom, significantly benefited from the decline in the Company’s share price at the expense of the Company’s shareholders. The Company believes this is criminal behavior and will continue to do what it can to protect the interests of its shareholders.
On December 22, 2023, the Company filed a motion to alternatively serve the Company’s summons and complaint upon Capybara and Appelboom by email. On December 26 2023, Senior Judge of the United States District Court for the Southern District of New York, The Honorable Jed S. Rakoff, entered an Order granting the Company’s motion. The Company’s counsel attempted to serve Capybara and Appelboom by email, however, in response to the motion and Order, Capybara and Appelboom have undertaken steps to intentionally evade service by deleting their respective email addresses.
Because of the evasive behavior exhibited by Capybara and Appelboom. That Safety Shot believes was an effort to avoid liability for their actions and preserve whatever anonymity they believe they have left, on January 8, 2024, the Company was required to serve a second motion for alternative service in which the Company sought permission to serve Capybara and Appelboom through their respective X accounts, through Capybara’s website’s contact page, by newspaper publication and through a public disclosure and press release. In response to the Company’s second motion, and consistent with its efforts to evade service, Capybara removed the contact page from its website and Appelboom deleted his X account. Both of these actions were taken in an effort to further evade service.
On January 10, 2024, in a historic, first-of-its-kind order, The Honorable Jed S. Rakoff granted the Company’s second motion permitting the Company to serve notice of the Action upon through this press release and associated Form 8-K filed on the Securities and Exchange Commission’s EDGAR database.
Pursuant to the Order of The Honorable Jed S. Rakoff in the United States District Court for the Southern District of New York, entered on January 10, 2024 (ECF 24), in the matter of Safety Shot, Inc. v. Capybara Research et. al., Case No. 1:23-cv-10728-JSR, this press release, the Form 8-K filed on January 11, 2024 and the exhibits to the Form 8-K containing the Company’s summons, complaint and the Court’s Order, hereby provides the Constitutional requirement of actual notice of the Action to Defendants Capybara Research and Igor Appelboom pursuant to Rule 4(f)(3) of the Federal Rules of Civil Procedure.
About Safety Shot
Safety Shot, a wellness and functional beverage company, is set to launch Safety Shot, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity. Safety Shot will be available for retail purchase in the first week of December 2023 at www.DrinkSafetyShot.com and www.Amazon.com. The Company plans to launch business-to-business sales of Safety Shot to distributors, retailers, restaurants, and bars in the first quarter of 2024. Safety Shot plans to spin off legacy assets from its Jupiter Wellness business to unlock value for shareholders.
Media Contact:
Phone: 904-477-2306
Email: Emily@PanatelidesPR.com
Investor Contact:
Phone: 561-244-7100
Email: investors@safetyshotholdings.com
Exhibit 99.2
Exhibit 99.3
Exhibit 99.4
1 Year Jupiter Wellness Chart |
1 Month Jupiter Wellness Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions